A case of hepatitis E that developed during chemotherapy for malignant lymphoma and responded to ribavirin

• Published in: Cancer reports Vol. 7; no. 2; pp. e1957 - n/a
• Main Authors: Hashimoto, Seiya, Fukuda, Hirofumi, Takeda, Kohei, Uchida, Keiichi, Sanuki, Fumiaki, Akiyama, Takashi, Kondo, Eisei, Wada, Hideho
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2024; John Wiley and Sons Inc; Wiley
• Subjects: Autoimmune diseases; Bile; Blood tests; Blood transfusions; Case Report; Case Reports; Chemotherapy; Drug dosages; Enzymes; Hematology; Hepatitis; hepatitis E virus; Hospitals; Immunosuppressive agents; Infections; Liver; Lymphoma; Patients; Remission (Medicine); ribavirin; Tomography; Veins & arteries; chemotherapy; hepatitis E virus; ribavirin
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.1957

Background The main differences in cases of sudden elevation of hepatic enzyme levels during immunochemotherapy are the reactivation of the hepatitis B virus or drug‐induced liver injury. Here, we report a case of acute liver injury caused by the hepatitis E virus (HEV) during chemotherapy for malignant lymphoma, wherein the patient was successfully treated for the hepatitis and resumed chemotherapy to completion. Case A 57‐year‐old woman visited her local doctor because she felt lightweight and tired. The patient underwent lower gastrointestinal endoscopy and was diagnosed with a malignant lymphoma of the small intestine (diffuse large B‐cell lymphoma). The patient had a history of oral consumption of undercooked pork liver to improve anemia and was diagnosed with acute hepatitis E. Conclusion This report highlights the successful treatment of HEV infection in a patient undergoing immunosuppressive therapy for malignant lymphomas. A novel aspect of this study is the safe and effective use of ribavirin, an antiviral medication, along with continued chemotherapy, which resulted in sustained virological response (SVR) and the completion of the planned chemotherapy regimen. This report also provides new insights into the management of HEV infections in immunosuppressed patients undergoing chemotherapy and emphasizes the importance of considering HEV as a potential cause of acute liver injury in such cases. The successful use of ribavirin along with continued chemotherapy offers a promising treatment strategy for clinicians to consider in similar scenarios.